

PROVINCIAL FUNDING SUMMARY

Lenalidomide (Revlimid) (in combo) bortezomib + dexamethasone for newly diagnosed Multiple Myeloma (pCODR 10141)

pERC Recommendation: Recommends with conditions
 For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: July 5, 2019

This information is current as of September 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Under provincial consideration		
SK	Funded	Sep 1, 2020	<ul style="list-style-type: none"> •In combination with Bortezomib and low-dose Dexamethasone (RVd) for treatment of newly diagnosed patients with multiple myeloma in whom stem cell transplantation is not intended •Patients should have good performance status, and treatment in the maintenance phase (with Lenalidomide and low-dose Dexamethasone alone) may continue until unacceptable toxicity or disease progression
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Under provincial consideration		
NB	Under provincial consideration		
NL	Under provincial consideration		
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.